CVSA at a glance
Covista Inc. (CVSA, SEC CIK 730464) filed its latest 10-K annual report on August 6, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Covista Inc. (CVSA) reported revenue of $2.0 billion (up 9.3% from FY2025) and net income of $251.6 million. Diluted EPS was $7.04.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Covista Inc. (CVSA) shares worth $2.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Gangadharan Manjunath on August 27, 2026 of 1,802 shares at $137.18 per share.
- In the last 90 days, CVSA insiders reported 0 open-market purchases ($0) and 5 open-market sales ($2.3M) on Form 4, a net sale of $2.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $2.0B
- +9.3% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$2.3M
- 13F holders
- 32 funds
- $2.5B · −1 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Business Overview
- Core business: Largest U.S. healthcare educator with 5 accredited institutions delivering nursing, medical, veterinary, social sciences education on campuses and online
- New emphasis: "Purpose at Scale" strategy focusing on expanding healthcare education access, employer integration, technology, and operational excellence
- Strategic shift: Expanded medical education in the U.K. via AUC satellite campus partnership with University of Lancashire (since 2019)
- Quantitative highlight: 10,680 total employees as of June 30, 2026, spanning full-time staff and professors across all segments
- Noteworthy fact: Fiscal year 2022 ED composite financial responsibility score dropped to 0.2, resulting in provisional Title IV certifications with $202.6M in surety-backed letters of credit
Management Discussion & Analysis
- Revenue $1,954.1M, up 9.3% YoY ($165.8M increase) driven by all segments: Chamberlain +3.4%, Walden +16.1%, Medical and Veterinary +8.1%
- Operating margin 19.6% vs 19.1%, adjusted operating margin 21.5% vs 20.7%; net income $251.6M up 6.1%, adjusted net income $294.7M up 15.3%
- Best segment: Walden adjusted operating income $239.7M, +30.6% YoY; Worst: Chamberlain adjusted operating income $143.6M, down 6.3%
- Cash flow: Operating cash flow $470.8M (+$137.1M); Capex $77.7M; Share repurchases $239.9M; Dividends not mentioned
- Outlook/risk: Management highlights focus on enrollment growth, cost control, capital structure optimization; risks include economic changes impacting liquidity and earnings
Risk Factors
- Regulatory risk: U.S. Department of Education Borrower Defense to Repayment regulations, potential liability and required $500M letters of credit limit under credit agreement
- Geopolitical/macroeconomic threat: Operations exposed to natural disasters, political disruptions, armed conflicts in U.S. West Coast, Gulf States, Caribbean impacting campuses
- Operational/supply chain risk: State governments may limit clinical placement affiliations for medical schools, restricting enrollment and growth potential
- Competitive disruption risk: Increasing competition from traditional colleges' growing online learning and technology-enabled programs threatens enrollment and tuition rates
- Financial/structural risk: Potential goodwill and intangible asset impairment up to $1.7B combined due to market cap decline or adverse operating results
AI summary of the CVSA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Management Discussion & Analysis
- Revenue $487.0M, up 4.5% YoY from $466.1M
- GAAP operating margin 18.8% vs 19.4% YoY; adjusted margin 21.0% vs 22.6%
- Medical and Veterinary strongest segment, revenue $103.5M, up 8.9%; Chamberlain weakest, up 2.3% to $197.0M
- Term Loan B refinancing $510.0M; $508.3M prior debt repaid
- Share repurchases 637,538 shares at average $103.04; cost pressures from labor, marketing, and growth investments
Risk Factors
- Risk Factors section not provided in submitted filing text
- Share repurchases: 637,538 shares bought at average $103.04
- Liquidity allocation: $661,811,630 remaining under repurchase plans
- Debt financing: Credit Agreement amended March 2, 2026
- Insider trading compliance: former CMO’s 10b5-1 Plan covers 8,753 shares
AI summary of the CVSA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $510 million term loans repriced, reducing Term SOFR margin from 2.25% to 2.00%
- Base-rate margin reduced from 1.25% to 1.00%, lowering Covista’s borrowing costs
Item 2.02: Results of Operations and Financial Condition
- Forward-looking statements reference Covista’s future growth, but provide no operating or financial results
- Investors should rely on the accompanying press release and filings for fiscal 2026 performance details
Item EX-99.1: Item EX-99.1
- Q4 revenue $501.4M, up 9.7%; adjusted EBITDA $126.9M, up 15.2%, with margin expanding to 25.3% from 24.1%
- FY2026 revenue $1,954.1M, up 9.3%; adjusted EPS $8.25, up 23.7%, and adjusted EBITDA margin reached 26.7%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Two independent directors, Emily Chiu and Leslie Storms, appointed effective August 17, 2026
- Board expanded from 10 to 12 members, increasing independent oversight capacity
Item EX-99.1: Item EX-99.1
- Emily C. Chiu and Leslie Storms appointed directors effective August 17, 2026
- Board expands technology, fintech, healthcare delivery, medtech and acquisition-integration expertise
AI summaries of CVSA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CVSA
Don't miss the next CVSA filing
- Alerts as it files. A push when CVSA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CVSA, by share count.
- Ask anything. An AI agent that reads every CVSA filing and answers with sources.
CVSA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MALAFRONTE MICHAEL W | G | Aug 31, 2026 | 2,500 | - |
| Gangadharan Manjunath | Sell | Aug 27, 2026 | 1,802 | $137.18 |
| Phelan Robert J. | A | Aug 23, 2026 | 10,080 | $132.35 |
| Beard, Stephen W. | F | Aug 23, 2026 | 23,543 | $132.35 |
| Phelan Robert J. | F | Aug 23, 2026 | 1,279 | $132.35 |
| Phelan Robert J. | A | Aug 23, 2026 | 7,056 | $132.35 |
| Phelan Robert J. | F | Aug 23, 2026 | 3,126 | $132.35 |
| Beard, Stephen W. | F | Aug 23, 2026 | 9,621 | $132.35 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.8B | $2.0B |
| Operating Income | $217.1M | $341.5M | $383.4M |
| Net Income | $136.8M | $237.1M | $251.6M |
| Op. Margin | - | 19.1% | 19.6% |
| Net Margin | - | 13.3% | 12.9% |
| Balance Sheet | |||
| Total Assets | - | $2.8B | $3.0B |
| Equity | - | $1.4B | $1.4B |
| ROE | - | 16.5% | 17.4% |
| Per Share | |||
| EPS | - | $6.18 | $7.04 |
| Cash Flow | |||
| Operating CF | $295.8M | $337.9M | $470.4M |
| CapEx | $48.9M | $50.3M | $77.7M |
Source: XBRL data in Covista Inc. (CVSA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CVSA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $2.50B |
| Q1 2026 | 33 | $2.25B |
| Q4 2025 | 30 | $1.89B |
| Q3 2025 | 31 | $2.91B |
| Q2 2025 | 31 | $2.47B |
| Q1 2025 | 27 | $1.39B |
| Q4 2024 | 23 | $1.07B |
| Q3 2024 | 19 | $519.4M |
- FMR LLC (Fidelity)+564.0K (+21%)
- T. Rowe Price Group+276.8K (+56%)
- BlackRock+250.8K (+5%)
- Morgan Stanley+53.8K (+13%)
- Wells Fargo & Co+46.4K (+83%)
- Two Sigma Investments−235.1K (-48%)
- Goldman Sachs Group−182.7K (-53%)
- JPMorgan Chase & Co−62.1K (-49%)
- Bank of America Corp−51.8K (-23%)
- Vanguard Portfolio Management LLC−34.6K (-1%)
- Citadel Advisors LLC−88.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 226 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CVSA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-K | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | May 20, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis |
Related Consumer Discretionary companies
- APEI · AMERICAN PUBLIC EDUCATION INCServices-Educational Services
- GHC · Graham Holdings CoServices-Educational Services
- LAUR · LAUREATE EDUCATION, INC.Services-Educational Services
- LINC · LINCOLN EDUCATIONAL SERVICES CORPServices-Educational Services
- NRDY · Nerdy Inc.Services-Educational Services
- PRDO · PERDOCEO EDUCATION CorpServices-Educational Services
- PXED · Phoenix Education Partners, Inc.Services-Educational Services
- STRA · Strategic Education, Inc.Services-Educational Services
CVSA SEC filings: frequently asked questions
Are CVSA insiders buying or selling?
In the last 90 days, Covista Inc. (CVSA) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $2.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CVSA stock?
As of June 30, 2026, the largest Covista Inc. (CVSA) holders among the 13F filers tracked by SignalX were BlackRock ($683.2 million), FMR LLC (Fidelity) ($401.2 million), Vanguard Portfolio Management LLC ($297.6 million), Dimensional Fund Advisors ($222.2 million), Vanguard Capital Management LLC ($183.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CVSA's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Covista Inc. (CVSA) reported revenue of $2.0 billion (up 9.3% from FY2025) and net income of $251.6 million. Diluted EPS was $7.04. The figures come from the XBRL data in the 10-K.
What are the main risks in CVSA's latest 10-K?
In the 10-K filed August 6, 2026, Covista Inc. (CVSA) flagged: Regulatory risk: U.S. Department of Education Borrower Defense to Repayment regulations, potential liability and required $500M letters of credit limit under credit agreement. Geopolitical/macroeconomic threat: Operations exposed to natural disasters, political disruptions, armed conflicts in U.S. West Coast, Gulf States, Caribbean impacting campuses. (AI summary of the Risk Factors section.)
What did CVSA report in its latest 8-K?
Covista Inc. (CVSA) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $510 million term loans repriced, reducing Term SOFR margin from 2.25% to 2.00%.
What are the latest CVSA SEC filings?
Covista Inc. (CVSA) filed its latest 10-K annual report on August 6, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 1, 2026.
What is CVSA's SEC CIK number?
Covista Inc. (CVSA)'s SEC Central Index Key (CIK) is 730464. EDGAR lists every CVSA filing under that number.
Ask anything about CVSA
The research agent reads CVSA's filings, financials, insider trades and 13F holders, then answers with sources.